Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results
July 19 2018 - 8:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a
conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern
Time (ET) to discuss the Company's fiscal first-quarter 2019
operating and financial highlights. In advance of the call on
August 9, 2018, Organovo will issue its fiscal first-quarter 2019
earnings press release, which will be available at
http://www.organovo.com. To participate in the
teleconference, callers can dial the following numbers:
1-888-317-6003 (toll-free, U.S. callers only)
1-412-317-6061 (from outside the U.S.)
Conference Call ID: 3834076
To help ensure the conference call begins in a timely manner,
please dial in five minutes prior to the scheduled start
time. The conference call will also be simultaneously webcast
at http://www.organovo.com.
For those unable to participate in the live call, a replay of
the call will be available toll-free until August 16, 2018 at
1-877-344-7529 (U.S. callers only) or at 1-412-317-0088 (callers
outside the U.S.). The passcode for the replay is:
10122205. An archived replay of the webcast will also be
available at http://www.organovo.com.
About Organovo Holdings, Inc.Organovo is a
biotech platform company that has developed a leadership position
with its revolutionary ability to 3D bioprint tissues with human
functionality. The Company is pursuing multiple IND-track
programs to develop its NovoTissues® to address a number of serious
unmet medical needs in adult and pediatric populations, initially
focusing on liver disease. Organovo’s first IND-track program
for Alpha-1-antitrypsin deficiency recently received orphan drug
designation from the FDA, and the Company expects to file its first
IND in 2020. In order to help fund its plan to initiate
multiple IND-track programs, the Company is providing access to its
ExVive™ in vitro tissue disease modeling platform to facilitate
high value drug discovery and development collaborations.
Organovo’s wholly-owned subsidiary, Samsara Sciences, provides the
Company and its clients with high quality human liver and kidney
cells for research applications. Organovo is changing the
shape of life science research and transforming medical care.
Learn more at www.organovo.com.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. Forward-looking statements include, but are
not limited to, statements regarding the potential for one or more
customer’s electing to move toward framework agreements involving
annual budgets, revenue commitments, and/or dedicated research
plans, statements regarding customer demand for and acceptance of
our disease modeling services and statements regarding the
potential benefits and therapeutic uses of the Company’s
therapeutic liver tissue, including the benefits of an orphan
designation. The factors that could cause the Company's
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products and services based on its technology; the
expected benefits and efficacy of the Company's products, services
and technology; the Company’s ability to execute framework
agreements involving multi-year commitments and routine use on a
timely basis, or at all; the Company’s ability to successfully
complete studies and provide the technical information required to
support market acceptance of its products, services and technology,
on a timely basis or at all; the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies, including its use of third party
distributors; the Company’s ability to recognize deferred revenue;
the final results of the Company's preclinical studies may be
different from the Company's studies or interim preclinical data
results and may not support further clinical development of its
therapeutic tissues; the Company may not successfully complete the
required preclinical and clinical trials required to obtain
regulatory approval for its therapeutic tissues on a timely basis
or at all; the Company’s ability to control the costs and to
achieve the expected operational benefits and long-term cost
savings of its restructuring plan; and the Company’s ability to
meet its fiscal-year 2019 goals and outlook. These and other
factors are identified and described in more detail in the
Company's filings with the SEC, including its Annual Report on Form
10-K filed with the SEC on May 31, 2018. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United States,
the Company does not intend to update any of the forward-looking
statements to conform these statements to reflect actual results,
later events or circumstances or to reflect the occurrence of
unanticipated events.
Investor & Press Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From May 2024 to Jun 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jun 2023 to Jun 2024